Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Lignende værker

• Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
  af: Leapman, Michael S., et al.
  Udgivet: (2020)
• Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
  af: Park, Jang-June, et al.
  Udgivet: (2021)
• Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
  af: Li, Wen-Qian, et al.
  Udgivet: (2020)
• Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
  af: Lee, Yong Jun, et al.
  Udgivet: (2021)
• Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids
  af: Sun, Lejia, et al.
  Udgivet: (2019)